How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1

Remdesivir is recommended as an option for treating COVID-19 in:

1.2

Tixagevimab plus cilgavimab is not recommended, within its marketing authorisation, for treating COVID-19 in adults who do not need supplemental oxygen and who have an increased risk of progression to severe COVID-19.

Why the committee made these recommendations

Most of the clinical evidence for remdesivir and tixagevimab plus cilgavimab is highly uncertain because it comes from studies done before the dominant Omicron variants of SARS-CoV-2 (the virus that causes COVID‑19). Also, some evidence does not reflect clinical practice at the time of this evaluation.

The cost-effectiveness estimates are highly dependent on how well each treatment works compared with standard care, and hospitalisation and mortality rates. Hospitalisation and mortality rates are lower with Omicron variants than earlier variants in the pandemic. These lower rates increase the cost-effectiveness estimates.

Remdesivir in adults

Clinical evidence suggests remdesivir is effective for treating mild COVID-19 in adults. Clinical evidence on remdesivir for treating COVID-19 in adults in hospital with pneumonia is highly uncertain. But, it suggests that remdesivir can improve survival for adults needing low-flow supplemental oxygen compared with standard care.

The cost-effectiveness estimates for remdesivir are only likely to be within what NICE considers a cost-effective use of NHS resources for adults in hospital with pneumonia who need low-flow supplemental oxygen and who have a high risk of serious illness. So, remdesivir is recommended for treating COVID-19 in this group.

Remdesivir in babies, children and young people

The committee considered remdesivir for babies, children and young people (aged 4 weeks to 17 years and weighing at least 3 kg) in hospital with pneumonia who need supplemental oxygen.

There is limited clinical evidence comparing remdesivir with standard care for treating severe COVID-19 in babies, children and young people in hospital with pneumonia who need supplemental oxygen. So the cost-effectiveness estimates are highly uncertain. But there are limited treatment options licensed for this group and the number who would have remdesivir is very small. So, remdesivir is recommended for treating COVID-19 in this group.

Tixagevimab plus cilgavimab in adults

Evidence suggests that it is highly uncertain that tixagevimab plus cilgavimab is effective against Omicron variants of COVID‑19. Because of this, it is not possible to reliably estimate its cost effectiveness, so it is not recommended.